3652 results for «303»
3652 results
The continuum of valvular heart disease: a lifetime management approach
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing...
DCB in contemporary PCI: evidence, technique and physiology-guided decision-making
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the evolving role of drug-coated balloons (DCB) in contemporary PCI, highlighting how growing clinical evidence, refined procedural strategies and physiology-guided tools are reshaping everyday practice.
The discussion reviews the latest data supporting DCB use, including long-term outcomes from major registries and trials...
Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX
21 May 2026 – From EuroPCR 2026
This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...
Evolving bifurcation treatment practices: DCB, angio-based FFR and side branch optimisation
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the evolving landscape of bifurcation PCI, focusing on drug-coated balloon (DCB) strategies, angio-based fractional flow reserve (FFR) and side branch optimisation. It highlights how new evidence and physiology-guided tools are reshaping decision-making in this complex lesion subset.
Discussions include insights from the...
Artificial intelligence-driven precision therapy for TAVI: progress and practice in China
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the integration of artificial intelligence into precision therapy for TAVI in China, highlighting its growing role in procedural planning, optimisation and outcome prediction.
Through case-based discussion, it shows how AI-enabled tools can simulate valve deployment and visualise post-TAVR results, supporting more precise...
When less is better - Differentiated therapies to safely achieve TR 0-1+
19 May 2026 – From EuroPCR 2026
Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.
This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...
Real world practice inspiring new evidence generation in structural heart
21 May 2026 – From EuroPCR 2026
This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
